izpis_h1_title_alt

The impact of SARS-CoV-2 primary vaccination in a cohort of patients hospitalized for acute COVID-19 during Delta variant predominance
ID Stupica, Daša (Author), ID Collinet-Adler, Stefan (Author), ID Kejžar, Nataša (Author), ID Jagodic, Zala (Author), ID Poljak, Mario (Author), ID Nahtigal Klevišar, Mirijam (Author)

.pdfPDF - Presentation file, Download (709,47 KB)
MD5: 05256BA6B0533FA1EBDCAF61ED12D9EB
URLURL - Source URL, Visit https://www.mdpi.com/2077-0383/11/5/1191 This link opens in a new window

Abstract
Vaccine breakthrough SARS-CoV-2 infections necessitating hospitalization have emerged as a relevant problem with longer time interval since vaccination and the predominance of the Delta variant. The aim of this study was to evaluate the association between primary vaccination with four SARS-CoV-2 vaccines authorized for use in the European Union—BNT162b2, ChAdOx-1S, mRNA-1273 or Ad.26.COV2.S—and progression to critically severe disease (mechanical ventilation or death) and duration of hospitalization among adult patients with PCR-confirmed acute COVID-19 hospitalized during the Delta variant predominance (October–November 2021) in Slovenia. Among the 529 enrolled patients hospitalized with COVID-19 (median age, 65 years; 58.2% men), 175 (33.1%) were fully vaccinated at the time of symptom onset. Compared with 345 unvaccinated patients, fully vaccinated patients with breakthrough infections were older, more often immunocompromised, and had higher Charlson comorbidity index scores. After adjusting for sex, age, and comorbidities, fully vaccinated patients had lower odds for progressing to critically severe disease and were discharged from the hospital earlier than unvaccinated patients. Vaccination against SARS-CoV-2 remains an extremely effective intervention to alleviate morbidity and mortality in COVID-19 patients.

Language:English
Keywords:COVID-19 vaccine, vaccine breakthrough, vaccination impact, COVID-19 outcome
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:10 str.
Numbering:Vol. 11, iss. 5, art. 1191
PID:20.500.12556/RUL-137279 This link opens in a new window
UDC:616.9
ISSN on article:2077-0383
DOI:10.3390/jcm11051191 This link opens in a new window
COBISS.SI-ID:98584067 This link opens in a new window
Publication date in RUL:09.06.2022
Views:1264
Downloads:101
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of clinical medicine
Shortened title:J. clin. med.
Publisher:MDPI
ISSN:2077-0383
COBISS.SI-ID:5405759 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.03.2022

Secondary language

Language:Slovenian
Keywords:cepivo za COVID-19, preboj cepiva, vpliv cepljenja

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P3-0154
Name:Metodologija za analizo podatkov v medicini

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back